We specialise in providing protein engineering to pharmaceutical and biotechnology companies for the discovery, identification and design of new peptide, polypeptide, protein and antibody compounds using our proprietary technology.

Working in partnership with our clients, we discover highly active lead candidates for drug development with the ultimate goal of identifying channels to market for these new and potent therapeutic peptides.

• Engineered Antibodies: Berlin, Germany, 13-14 June - Dr Chris Ullman and Mr Garry Merry
• Next Generation Protein Therapeutics: San Francisco, CA, 25-27 June - Dr Pascale Mathonet

CURRENT VACANCIES >

• Isogenica secures European Framework 7 grant worth up to €700,000 More

• Isogenica announces latest board level appointment More

• Isogenica expands discovery capacity with investment in new automation facility More

• Isogenica, Biolauncher and Cresset Biomolecular Discovery forge alliance to bring powerful target-to-drugs platform to
  market More

• Isogenica expands business development and customer support Ops in North USA More

• Isogenica announces colloboration with Johnson and Johnson Pharmaceutical Research and Development LLC More

• Isogenica and Australian drug discovery company Phylogica announce successful technology collaboration More

• Isogenica announces new collaboration with Prof Sir Tom Blundell of the University of Cambridge More

• Isogenica announces new colloboration with Novabiotics More